Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Baxter

Last Updated: August 15, 2022

CAMBIA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Cambia patents expire, and when can generic versions of Cambia launch?

Cambia is a drug marketed by Assertio and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-three countries.

The generic ingredient in CAMBIA is diclofenac potassium. There are forty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cambia

A generic version of CAMBIA was approved as diclofenac potassium by TEVA on August 6th, 1998.

  Try it Free

Drug patent expirations by year for CAMBIA
Drug Prices for CAMBIA

See drug prices for CAMBIA

Drug Sales Revenue Trends for CAMBIA

See drug sales revenues for CAMBIA

Paragraph IV (Patent) Challenges for CAMBIA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CAMBIA Oral Solution (Sachet) diclofenac potassium 50 mg 022165 1 2011-01-24

US Patents and Regulatory Information for CAMBIA

CAMBIA is protected by four US patents.

Patents protecting CAMBIA

Diclofenac formulations and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

Diclofenac formulations and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

Diclofenac formulations and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

Diclofenac formulations and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CAMBIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 See Plans and Pricing See Plans and Pricing
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CAMBIA

See the table below for patents covering CAMBIA around the world.

Country Patent Number Title Estimated Expiration
Mexico 2007016072 FORMULACIONES DE DICLOFENAC Y METODOS PARA USARLAS. (DICLOFENAC FORMULATIONS AND METHODS OF USE.) See Plans and Pricing
South Korea 101352130 See Plans and Pricing
New Zealand 332655 Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates See Plans and Pricing
China 101272768 Diclofenac formulations and methods of use See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Boehringer Ingelheim
Medtronic
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.